Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First report of cancer drug Gleevec as new target therapy for pulmonary hypertension

30.09.2005


Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension. „In cancer, tissue proliferation is uncontrolled and leads to the spreading of the tumor," primary investigator Prof. Friedrich Grimminger of the University of Giessen Lung Center explained. "In pulmonary hypertension, also, uncontrolled growth of the vascular wall is the underlying mechanism of the disease." Pulmonary hypertension is a chronic and life-shortening vascular disease characterized by high pressure in the lung blood vessels. The relatively common condition can occur for many reasons such as heart disease and various acute and chronic lung ailments. As a result, the pulmonary arteries thicken and stiffen, causing high blood pressure and right heart hypertrophy.



In a translational research approach, taking their research "from bench to bedside", Dr. Ralph Schermuly of the same German center only recently described the successful use of Gleevec (Imatinib) in two well established experimental models of progressive pulmonary arterial hypertension. His group found, that the treatment resulted in virtually complete reversal of lung vascular remodeling, pulmonary hypertension and right heart hypertrophy. The common findings suggest, that Gleevec’s uses might expand even further. Co-researcher Dr. Ardeschir Ghofrani is convinced, that the results of their studies may open a completely new therapeutic field of targeted treatment for chronic proliferative diseases such as atherosclerosis, COPD, lung emphysema or lung fibrosis.

Larger clinical trials in a controlled design to test Gleevec’s safety and effectiveness are currently in preparation under the scientific lead of the Giessen lung researchers, who also signed largely responsible for the recent appproval of RevatioTM (Sildenafil) for the treatment of pulmonary hypertension in the US.


The UGLC constitutes an interdisciplinary scientific network incorporating 20 research groups with more than 120 basic scientists and clinicians, focusing on pulmonary research and treatment of lung diseases at the University Hospital Giessen, Germany.

Friedrich Grimminger, MD | EurekAlert!
Further information:
http://www.uglc.de

More articles from Studies and Analyses:

nachricht Climate change and air pollution damaging health and causing millions of premature deaths
30.11.2018 | International Institute for Applied Systems Analysis (IIASA)

nachricht Reading rats’ minds
29.11.2018 | Institute of Science and Technology Austria

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

Im Focus: The force of the vacuum

Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.

The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

New method gives microscope a boost in resolution

10.12.2018 | Physics and Astronomy

Carnegie Mellon researchers probe hydrogen bonds using new technique

10.12.2018 | Life Sciences

ETRI exchanged quantum information on daylight in a free-space quantum key distribution

10.12.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>